Issues
-
Cover Image
Cover Image
Targeted therapies and immune checkpoint inhibitors (ICI) are effective treatments for melanoma, but efforts to combine these therapeutic modalities have been unsuccessful. Using mouse models of BRAF- and NRAS-mutant melanoma, Phadke et al. show that administration of an anti–PD-1 ICI before targeted therapy results in sustained antitumor immunity that leads to durable tumor responses. Single-cell RNA sequencing analysis shows that the sequential treatment alters the tumor immune microenvironment, promoting tumor infiltration by T cells, monocytes, dendritic cells, and natural killer cells, and simultaneously decreasing infiltration by tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells. The melanoma cells also have signatures characteristic of enhanced immunogenicity and no signatures associated with resistance to the targeted therapies. The study has implications for future development of combinations of targeted therapies and ICIs. Read more in this issue on page 554. Original image from work by Phadke et al. that is related to the article but not included in the final publication. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We’re Reading
In the Spotlight
Review
Research Articles
Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.